Cencora Files Quarterly 10-Q Report With SEC
The pharmaceutical distribution giant submitted its latest quarterly disclosures as the company prepares for an upcoming dividend payment.
Regulatory Filing
Cencora, Inc. (NYSE: COR) filed its quarterly report on Form 10-Q with the Securities and Exchange Commission on August 5, 2026, according to SEC EDGAR filings. The pharmaceutical distribution company, with a market capitalization of approximately $62 billion, closed at $325.01 in its most recent trading session.
The 10-Q filing provides investors and regulators with a comprehensive view of the company's financial performance and operational developments for the quarter, including unaudited financial statements and management's discussion of results.
Upcoming Corporate Actions
Cencora has declared a cash dividend of $0.60 per share, payable on August 14, 2026, according to MarginX data. The dividend payment comes just over a week following the quarterly filing, maintaining the company's regular shareholder return schedule.
The company is expected to report its full Fiscal Year 2026 results on November 4, 2026, which will provide a comprehensive view of annual performance in the pharmaceutical distribution sector.
Recent Insider Activity
MarginX data shows recent equity awards to company insiders, with Cooper Ellen and Tyler Lauren M each receiving awards of 97 shares, while Dennis M. Nally was granted 113 shares. These awards are typical components of executive compensation packages at large pharmaceutical distributors.
Market Context
The filing comes ahead of two Federal Open Market Committee meetings scheduled for September 16 and October 28, 2026. The September meeting will include updated economic projections, which could impact interest rate-sensitive sectors including healthcare distribution.
As a major pharmaceutical distributor in the United States, Cencora plays a critical role in the healthcare supply chain, serving pharmacies, health systems, and pharmaceutical manufacturers. The company's quarterly disclosures provide transparency into operational trends within the broader pharmaceutical distribution industry.
This article was generated by MarginX from public news on 2026-08-05. It is not investment advice.